kaken KP-496 Pages on BioPortfolio:

BioPortfolio kaken KP496
kaken KP-496 - BioPortfolio. ... Recent Publications by Kaken Pharmaceutical Co Limited Effects of KP496 a novel dual antagonist at the cysteinyl ...
http://www.bioportfolio.com/search/kaken_KP-496.html...

BioPortfolio - Kaken Pharmaceutical Co Limited
Recent Publications by Kaken Pharmaceutical Co Limited:. Effects of KP-496, a novel dual antagonist at the cysteinyl leukotriene receptor 1 and the ...
http://www.bioportfolio.com/biocorporate/5990-Kaken_Pharmace...

BioPortfolio Kaken Pharmaceutical Co Limited
BACKGROUND AND PURPOSE KP496 is a novel dual antagonist for cysteinyl, 15th May 2008, Pharmacology Department Central Research Laboratories Kaken ...
http://www.bioportfolio.com/biocorporate/5990-Kaken%2BPharma...

BioPortfolio Kaken Pharmaceutical Co Limited
KP496 montelukast and seratrodast were synthesized by Kaken Pharmaceutical Co LtdTokyo Japan A dry powder formulation of KP496KP496DPI ...
http://www.bioportfolio.com/search/Kaken_Pharmaceutical_Co_L...

BioPortfolio patent Careload
Recent Search Terms used to find this page kaken KP496 | patent Careload | KP496 | Search for more companies in Chiba Search for more companies in ...
http://www.bioportfolio.com/search/patent_Careload__.html...

Results from other life science and pharmaceutical sites:

British Journal of Pharmacology - Abstract of article: Effects of ...
Effects of KP-496, a novel dual antagonist at the cysteinyl leukotriene receptor 1 and ... 1Pharmacology Department, Central Research Laboratories, Kaken ...
http://www.nature.com/bjp/journal/v153/n4/abs/0707602a.html...

Effects of KP-496, a novel dual antagonist at the ...[Br J ...
Ltd, Kyoto, Japan. ishimura_masakazu@kaken.co.jp. BACKGROUND AND PURPOSE: KP-496 is a novel dual antagonist for cysteinyl leukotriene receptor 1 (CysLT(1)) ...
http://www.ncbi.nlm.nih.gov/pubmed/18037905...

British Journal of Pharmacology - Effects of KP-496, a novel dual ...
KP-496, montelukast and seratrodast were synthesized by Kaken Pharmaceutical Co. Ltd (Tokyo, Japan). A dry powder formulation of KP-496 (KP-496DPI, ...
http://www.nature.com/bjp/journal/v153/n4/full/0707602a.html...

Effects of KP-496, a novel dual antagonist for leu...[Allergol Int ...
Pharmacology Department, Central Research Laboratories, Kaken ... CONCLUSIONS: These results indicate that KP-496 is a selective dual antagonist for LTD(4) ...
http://www.ncbi.nlm.nih.gov/pubmed/17130683...

American Academy of Allergy, Asthma & Immunology – 2008 Annual Meeting
Masahiro Suda from Kaken Pharmaceutical Co Ltd described. an asthma study that evaluated the effects of an inhaled. formulation of the company's KP-496, ...
http://www.biomedcentral.com/content/pdf/cd-900102.pdf...

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.